New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:50 EDTABBVAbbVie raises FY14 adjusted EPS to $3.06-3.16 from $3.00-$3.10, consensus $3.14
The company is raising its outlook, reflecting strong underlying business performance year to date and the expected continued positive trends over the remainder of the year, including the second quarter.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 16, 2015
10:10 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
Subscribe for More Information
07:04 EDTABBVEnanta says EU grants marketing authorizations for AbbVie's Viekirax
Subscribe for More Information
05:05 EDTABBVAbbVie granted marketing authorization by EC for VIEKIRAX + EXVIERA
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX + EXVIERA. The treatment has been approved with or without ribavirin for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
January 15, 2015
11:20 EDTABBVGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use